11553 related articles for article (PubMed ID: 12296474)
1. Biological response modifiers in cancer therapy.
Gupta S; Kanodia AK
Natl Med J India; 2002; 15(4):202-7. PubMed ID: 12296474
[TBL] [Abstract][Full Text] [Related]
2. Biological response modifiers: current use and future prospects in cancer therapy.
Bisht M; Bist SS; Dhasmana DC
Indian J Cancer; 2010; 47(4):443-51. PubMed ID: 21131760
[TBL] [Abstract][Full Text] [Related]
3. Biological Response Modifiers Programme and cancer chemotherapy.
Oldham RK
Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
[TBL] [Abstract][Full Text] [Related]
4. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
5. Biotherapy in clinical practice.
Figlin RA
Semin Hematol; 1989 Jul; 26(3 Suppl 3):15-24. PubMed ID: 2477904
[TBL] [Abstract][Full Text] [Related]
6. Biologic therapy in patients receiving salvage treatment.
Bukowski RM
Semin Oncol; 1994 Aug; 21(4 Suppl 7):96-9. PubMed ID: 8091247
[TBL] [Abstract][Full Text] [Related]
7. Cancer therapy by biological response modifiers.
Herberman RB
Clin Physiol Biochem; 1987; 5(3-4):238-48. PubMed ID: 2441918
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
Maloney DG
J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
[TBL] [Abstract][Full Text] [Related]
9. Cancer treatment: what's ahead?
Parvez T
J Coll Physicians Surg Pak; 2005 Nov; 15(11):738-45. PubMed ID: 16300718
[TBL] [Abstract][Full Text] [Related]
10. Immunological approach in the diagnosis, therapy and prognosis of the exocrine pancreatic cancer.
Bădulescu F; Bădulescu A; Rogoz S; Mustaţă R
Roum Arch Microbiol Immunol; 2001; 60(1):5-16. PubMed ID: 11850897
[TBL] [Abstract][Full Text] [Related]
11. The role of interferons in the treatment of malignant neoplasms.
Murren JR; Buzaid AC
Yale J Biol Med; 1989; 62(3):271-90. PubMed ID: 2479178
[TBL] [Abstract][Full Text] [Related]
12. Design of combination biotherapy studies: future goals and challenges.
Gilewski TA; Golomb HM
Semin Oncol; 1990 Feb; 17(1 Suppl 1):3-10; discussion 38-41. PubMed ID: 1689077
[TBL] [Abstract][Full Text] [Related]
13. New antineoplastic therapies and inherent risks: monoclonal antibodies, biologic response modifiers and interleukin-2.
Dillman JB
J Intraven Nurs; 1989; 12(2):103-13. PubMed ID: 2475596
[TBL] [Abstract][Full Text] [Related]
14. [A drug delivery system and biological response modifiers for the treatment of mycobacterial infection].
Koga H; Miyazaki Y; Kohno S; Hara K
Kekkaku; 1994 Feb; 69(2):113-8. PubMed ID: 8126987
[TBL] [Abstract][Full Text] [Related]
15. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy as part of combinations for the treatment of cancer.
Mitchell MS
Int Immunopharmacol; 2003 Aug; 3(8):1051-9. PubMed ID: 12860162
[TBL] [Abstract][Full Text] [Related]
18. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
19. Biologic response modifiers in cancer therapy: a review.
Quesada JR
Tex Med; 1989 Nov; 85(11):42-7. PubMed ID: 2686076
[TBL] [Abstract][Full Text] [Related]
20. Advances in chemotherapy for colorectal cancer.
Bernold DM; Sinicrope FA
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):808-21. PubMed ID: 16797250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
